62
Participants
Start Date
April 26, 2018
Primary Completion Date
September 4, 2021
Study Completion Date
August 5, 2022
Tocilizumab
Tocilizumab will be administered as per the schedule specified in the arm description.
NSAIDs
Participants may receive NSAIDs up to the maximum recommended stable daily dose. Study protocol does not enforce any particular NSAID.
CSs
Participants may receive CSs at a stable dose of 30 milligrams per day (mg/day) or 0.5 milligrams per kilogram per day (mg/kg/day), whichever is less. Study protocol does not enforce any particular CS.
MTX
Participants may receive MTX at a stable dose of less than or equal to (\</=) 20 milligrams per square meter (mg/m\^2).
Capital Institute of Pediatrics, Beijing
Beijing Children's Hospital, Capital Medical University; rheumatism, Beijing
The First Hospital of Jilin University, Changchun
Shanghai Children's Medical Center; Renal rheumatology, Shanghai
Children's Hospital of Fudan University, Shanghai
Chilren's hospital of nanjing medical university; Rheumatoid immunology, Nanjing
The Children's Hospibal ZheJiang University School of Medicine, Hangzhou
The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical College, Wenzhou
Children's Hospital Chongqing Medical university, Chongqing
Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Pediatric Rheumatology division, Guangzhou
Hoffmann-La Roche
INDUSTRY